Background: The unique responsiveness of Vc9Vd2 T-cells, the major cd subset of human peripheral blood, to non-peptidic prenyl pyrophosphate antigens constitutes the basis of current cd T-cell-based cancer immunotherapy strategies. However, the molecular mechanisms responsible for phosphoantigen-mediated activation of human cd T-cells remain unclear. In particular, previous reports have described a very slow kinetics of activation of T-cell receptor (TCR)-associated signal transduction pathways by isopentenyl pyrophosphate and bromohydrin pyrophosphate, seemingly incompatible with direct binding of these antigens to the Vc9Vd2 TCR. Here we have studied the most potent natural phosphoantigen yet identified, (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMB-PP), produced by Eubacteria and Protozoa, and examined its cd T-cell activation and anti-tumor properties.
Introduction
The capacity to recognize and eliminate transformed cells is common to several lymphocyte subsets of both the adaptive and the innate immune systems that are being targeted in cancer immunotherapy [1, 2] . One population that appears to bridge these two systems in humans is characterized by the expression of a Vc9Vd2 T-cell receptor and represents 1-10% of peripheral blood lymphocytes (PBL) of healthy individuals, but expands up to 30-50% upon bacterial or protozoan infection [3] .
In line with the cancer susceptibility phenotype of mice devoid of cd T-cells [4] , human Vc9Vd2 T-cells are endowed with notable anti-tumor activity toward a large spectrum of malignant cell lines of diverse tissue origin, particularly among lymphomas and leukemias [5] , but also including melanomas and carcinomas [6] , and are being explored in various clinical trials [7, 8] . Unexpectedly, Vc9Vd2 cells were shown to respond to self-and foreign non-peptidic low molecular weight antigens with phosphate moieties (''phosphoantigens''), in what turns out to be an exclusive property of this lymphocyte subset [9, 10, 11] . Indeed, no other human T-cell subset (namely Vd1 cells), or any of the murine cd populations, respond to phosphoantigens such as prenyl pyrophosphates [3] .
From its early isolation from mycobacteria, isopentenyl pyrophosphate (IPP) [10] became the model phosphoantigen for studies on Vc9Vd2 activation. However, it is now clear that this class of compounds contains multiple members, either naturally occurring or synthetic, which span an extremely diverse range of bioactivities, up to 10 10 fold differences. To date, the natural phosphoantigen with highest bioactivity known (32 picomolar) is (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMB-PP), an intermediate of the 2-C-methyl-D-erythritol 4-phosphate (MEP) pathway employed by Eubacteria and apicomplexan Protozoa but not by eukaryotes [12] . Although HMB-PP is respectively 30,000 and 100 times more potent than IPP and bromohydrin pyrophosphate (BrH-PP, also known as ''Phosphostim''), most of the studies on phosphoantigens have been performed with these compounds (already applied in the clinic) due to their historical precedence [3] . Such studies revealed a very slow kinetics of activation of TCR-associated signal transduction pathways, and conflicting results regarding their potential interactions with the Vc9Vd2 TCR [12, 13, 14] . This, added to the consistent failure to demonstrate cognate interactions between Vc9Vd2 TCRs and phosphoantigens in acellular systems [15] , has shed some skepticism regarding the action of phosphoantigens as direct TCRcd agonists. As HMB-PP is considered for cd T-cell-based cancer clinical trials, hoping to improve the performance of previous phosphoantigens [7, 8] , it is crucial to clarify its own molecular/cellular mechanisms of action, including its potential capacity to trigger bona fide Vc9Vd2 TCR signaling. Consistent with such potential, it has been recently shown that HMB-PP has the capacity to induce the formation of high-density TCR nanoclusters on the surface of human cd T-cells [16] , and a newly-developed tetramer reagent for the Vc9Vd2 TCR of rhesus macaques was reported to bind to HMB-PP loaded on the surface of human antigen presenting cells (APC) [17] .
In this study we have analyzed the intracellular effects of HMB-PP stimulation of human cd T-cells. Our data show that HMB-PP induces the activation of MEK/Erk and PI-3K/Akt signaling pathways with similar kinetics to direct cross-linking of the TCR complex in human cd T-cells, and requires those activities to mediate effective cd T-cell activation, including a full repertoire of TCR-associated transcriptional signatures and the secretion of pro-inflammatory cytokines IFN-c and TNF-a. Although TCR accessibility is required for HMB-PP activity, this phosphoantigen does not lead to ligand-induced TCR internalization, which appears to be advantageous for sustaining the cells' activation status upon re-stimulation. Finally, very low amounts of HMB-PP in conjugation with interleukin-2 (IL-2) confers human cd T-cells with very potent anti-lymphoma/leukemia activity both in vitro and in a human/SCID mouse model for the transplantation of human tumors, thus attesting the therapeutic potential of HMB-PP for cancer immunotherapy.
Results
Nanomolar amounts of HMB-PP replicate saturating TCR/ CD3 ligation for activation of Vc9 + T-cells
In this study we used the anti-CD3e monoclonal antibody (aCD3 mAb) OKT3 as a control for canonical T-cell activation through the TCR/CD3 complex, for direct comparison with HMB-PP. We began by testing the effect of several doses of each stimulating compound on human cd T-cell activation, proliferation and survival. Concentrations of 1 nM HMB-PP and 1 mg/ml OKT3 produced identical profiles of expression of the activation marker CD69 in the Vc9 + T-cell population ( Figure 1A) , and displayed strikingly similar kinetics of activation without significant differences in cell viability ( Figure 1B) ; they were therefore used in all subsequent experiments. Interestingly, whereas aCD3 mAb treatment reached a plateau of 60% CD69
+ cells at 1-10 mg/ml OKT3, 10 nM of HMB-PP were able to further increase the abundance of activated Vc9
+ T-cells, to above 80% ( Figure 1A ). Activated Vc9Vd2 T-cells are known to secrete large amounts of IFNc and TNFa, very potent anti-tumor mediators in vivo. In accordance, treatment of sorted cd PBL (80-95% Vc9 + ) with HMB-PP induced a typical Th1 cytokine profile, characterized by the preferential production of TNFa, IFNc and LTa, in the absence of significant IL-4 or IL-10 ( Figure 1C) . Notably, the levels of Th1 cytokines produced after 1 nM HMB-PP treatment were similar to those induced by saturating amounts of aCD3 mAb ( Figure 1C and data not shown), suggesting that low amounts of this phosphoantigen are able to fully exploit the TCR-mediated functional potential of Vc9Vd2 T-cells.
For the selective expansion of Vc9 + T-cells, HMB-PP has the advantage of not inducing ab T-cell proliferation. Thus, HMB-PP treatment promoted the specific proliferation of Vc9 + T-cells within human PBL ( Figure 1D ). Importantly, this effect was completely abolished upon addition of a blocking antibody to the Vc9 + TCR ( Figure 1E ), demonstrating the TCR-dependence of HMB-PP activity.
While HMB-PP alone promoted up to 5 divisions of Vc9 + Tcells over 4 days, further proliferation required the co-administration of IL-2 ( Figure 1D ). A cooperative effect between phosphoantigens and IL-2 has been previously described [18, 19] , and in this study translated into a Vc9 + T-cell expansion of 30-fold within one week and 45-fold within two weeks of stimulation ( Figure S1A ). Moreover, addition of 100 units/mL IL-2 to HMB-PP cultures dramatically increased the total amounts of Th1 cytokines secreted by cd T-cells by 20-80 fold ( Figure S1B ), which correlated with the induction of key transcription factor t-bet in cells stimulated with IL-2 or IL-2/HMB-PP combination ( Figure S1C) HMB-PP rapidly triggers MEK/Erk and PI-3K/Akt signaling required for Vc9 + T-cell activation and anti-tumor function
Having characterized the cellular behavior of HMB-PPstimulated Vc9
+ T-cells, we next investigated the intracellular signaling mechanisms downstream of HMB-PP. Previous studies with less active phosphoantigens [3] reported a significant delay in the activation of kinase cascades when compared to direct TCR/ CD3 complex ligation with OKT3 mAb [12, 13] . Instead, for HMB-PP, we observed a very rapid (peaking around 7 min of stimulation), and absolutely identical to OKT3, kinetics of phosphorylation of the major signaling pathways implicated in TCR signal transduction: JNK, Erk and p38 MAPK; and PI-3K-associated Akt and GSK3b (Figure 2A, left panel) . The same was valid in the presence of IL-2, in which kinase phosphorylation peaked earlier (immediately after 1 min of stimulation) but was still identical for HMB-PP or OKT3 combinations (Figure 2A , right panel). Of note, we verified that IPP could not replicate these signaling properties of HMB-PP, as illustrated by its failure to induce Akt phosphorylation within 60 minutes of stimulation ( Figure S2 ). Furthermore, IPP treatment (even when used at 10 5 fold higher concentrations than HMB-PP) resulted in a modest production of TNFa and IFNc within the first 6 hours of stimulation, when compared to HMB-PP ( Figure 2B ). These data reveal a thus far unique capacity of HMB-PP to trigger very rapid TCR-associated signaling, compatible with direct binding of the phosphoantigen to the TCR complex.
We next tested the requirement on intact PI-3K and MAPK pathways for cd T-cell activation and anti-tumor function induced by HMB-PP. We pre-treated cd T-cells with chemical inhibitors that specifically block those pathways and then analyzed the effects on cell activation, proliferation, TNFa secretion and tumor cell killing. Inhibition of PI-3K/Akt pathway using LY294002 resulted in approximately half of the cells losing their responsiveness to HMB-PP after 24-46 hours of stimulation ( Figure 3A) . Inhibition of the MEK/Erk pathway by UO126 produced even more dramatic effects, precluding HMB-PP-activation of approximately two thirds of Vc9 + T-cells. Moreover, inhibition of PI-3K/Akt and MEK/Erk signaling reduced TNFa production by HMB-PPactivated cd T-cells to around 20% and 10% of control levels, respectively, both in the absence and in the presence of IL-2 ( Figure 3B ). These effects were remarkably mirrored in cultures supplied with aCD3 mAb, further demonstrating the similarity of these two activation regimens ( Figures 3A and 3B) .
In what regards cd T-cell proliferation induced either by HMB-PP or by OKT3 (in the presence of IL-2), this was mostly dependent on intact PI-3K/Akt signaling, since UO126 had a more modest effect when compared with the severe block produced by LY294002 treatment, which reduced the proportion of cd cells that divided twice or more over 4 days in culture, from over 80% to approximately 20% ( Figure 3C) .
Finally, the anti-tumor function of sorted cd PBL (80-95% Vc9 + ) was assessed through in vitro killing of the Jurkat leukemic target cell line. HMB-PP pre-treatment augmented cd T-cellmediated tumor cell death from around 20% (non-activated cd) to 40% (1 nM HMB-PP) or 70% (10 nM HMB-PP) in a 6 hour assay ( Figure 3D and data not shown). However, the addition of UO126 or/and LY294002 to the treatment reduced posterior leukemia targeting to basal (20-30%) levels; this was also the case for the more efficient (over 80% killing) combination of HMB-PP with IL-2 ( Figure 3D ). Collectively, these data demonstrate an absolute requirement of PI-3K/Akt-and MEK/Erk-mediated signal transduction for HMB-PP-induced activation of anti-tumor Vc9Vd2 T-cells.
HMB-PP signaling mimics the transcriptional events downstream of TCR ligation
Signaling cascades ultimately produce alterations in gene transcription, which can be effectively tracked by microarray analysis. We employed this technology to compare the transcriptomes of Vc9Vd2 T-cells activated with either HMB-PP or OKT3. Both stimuli produced dramatic transcriptional changes: when compared to non-stimulated cells, HMB-PP and OKT3 treatment resulted in 1359 and 1080 differences in gene expression of 4-fold or above, respectively ( Figure 4A ; full microarray data available on ArrayExpress via http://www.ebi.ac.uk/; accession E-MEXP-1601). These were consistent across 3 individual microarray experiments ( Figure S2 ). Strikingly, a direct comparison of the two stimuli revealed that they affected essentially the same genes, as only 6 were differentially expressed (.4-fold) between them (Table 1) . Therefore, the transcriptional program downstream HMB-PP appears to be extremely similar to that induced by bona fide TCR signaling, as clearly illustrated by the Volcano plots of Figure 4A .
The gene expression program shared by HMB-PP treatment and direct TCR cross-linking involves, among many others targets (E-MEXP-1601), the very high (above 16-fold) up-regulation of pro-inflammatory genes IFNc and LTa, chemokines CCL8, CCL2, CXCL9 and CXCL10, cell cycle mediator cyclin D2, activation co-receptor ICOS, cytolysis mediator Fas ligand (Fas-L), and components of cytokine receptors IL-2Ra (CD25) and IL15Ra (Table 1) , many of which are also induced by related phosphoantigens [20] . These results were validated by quantitative real-time PCR (qPCR), as shown on Figure 4B for a selection of genes.
Although we have concentrated here on genes upregulated upon stimulation, the profile of downregulated genes was also almost identical between the two treatments (E-MEXP-1601). Our results collectively suggest that HMB-PP essentially recapitulates the transcriptional program associated with bona fide TCR signaling. This phenomenon is further illustrated by a heatmap representation of gene expression levels across the samples, as depicted in Figure S3 .
HMB-PP does not induce Vc9
+ TCR internalization and sustains the production of anti-tumor cytokines Although our previous data demonstrated a striking parallel between HMB-PP-and OKT3-mediated cd T-cell activation, previous reports on various phosphoantigens (other than HMB-PP) had revealed contradictory data on the modulation of surface Vc9Vd2 TCR levels [13, 14] . This, added to recent data on the properties of HMB-PP interactions with TCR/CD3 complexes [16, 17] , prompted our investigation on whether HMB-PP stimulation induced TCR internalization in human cd PBLs. In ab T cells, activation by cognate antigen or anti-TCR/CD3 antibodies typically induces TCR internalization and consequently the down-modulation of its surface levels independently of the constitutive recycling of the complex [21, 22] . Using two independent approaches, based on flow cytometry ( Figure 5A ) or confocal microscopy ( Figure 5B ), we consistently observed that HMB-PP-stimulated cd T-cells maintained their high TCR surface expression, in stark contrast with the extensive downregulation seen in OKT3-treated cells. This was the case both in the absence and in the presence of IL-2 (data not shown).
We next asked whether the lack of TCR internalization upon HMB-PP treatment could be associated with sustained activation of cd T-cells. We tested the capacity of cells that had been treated for 2 days with either HMB-PP or OKT3, to respond to a second boost of stimulation ( Figure 5C ). Whereas HMB-PP-treated cells, which maintained high TCR levels on the cell surface after the initial 48 hour treatment ( Figure 5A ), produced high amounts (similar to primary activation) of anti-tumor Th1 cytokines in response to the secondary 24 hour stimulation with HMB-PP ( Figure 5D ), OKT3-treated cells failed to do so, presumably due to their inability to respond to the mAb once their TCR complexes have been internalized (Figure 5A-B) . Although upon restimulation with HMB-PP, IFNc became more abundant than TNFa ( Figure 5D ), contrary to the primary activation data ( Figure 1C and Figure S1B ), the cytokine profile of the two HMB-PP-based protocols were qualitatively very similar and consistently Th1-biased ( Figure 5D and data not shown). These data show that HMB-PP is remarkably capable of sustaining Vc9Vd2 T-cell activation and the production of anti-tumor cytokines, which are critical parameters in immunotherapy protocols.
HMB-PP plus IL-2 treatment promotes leukemia cell killing in vitro and in vivo
Having characterized the intracellular mechanisms of HMB-PP-mediated cd T-cell activation, we next evaluated the antitumor potential of HMB-PP-based regimens. We selected Table 1 ). Gene expression was quantified in independent samples of control and treated cells, also including an IL-2-treated sample. Error bars represent SD and significant differences refer to ''resting'' cells (n = 3, *p,0.05 and **p,0.01). doi:10.1371/journal.pone.0005657.g004 leukemias as model tumors to employ in both in vitro and in vivo assays. The in vitro system previously used with Jurkat cells ( Figure 3D ) was applied to a larger panel of leukemia cell lines: Molt-4 (T-cell), RCH-ACV (pre-B cell) and HL-60 (myeloid) (Figures 6A-B) . cd PBL (80-95% Vc9 + ) were treated with the different stimulating agents for 72 hours, and then transferred to plain media in co-culture with the leukemia cells. In just 3 hours, more than 80% of leukemia cells were killed by the cd T-cells that had been stimulated with a combination of HMB-PP with IL-2 (compared to less than 20% by non-activated cd T-cells), and such a regimen was at least as effective as saturating aCD3 plus IL-2 ( Figures 6A-B) . Of note, aCD3 mAb or HMB-PP used in isolation produced more modest increases in target-cell lysis ( Figures 6A-B) , highlighting the importance of exogenous IL-2 for the full activation of Vc9Vd2 T-cells [18, 23] (Figure S1 ).
Taking into account the added relevance of pre-clinical in vivo systems for the evaluation of the anti-tumor potential of immunotherapy strategies, we adapted a model of transplantation of human tumors into lymphopenic SCID mice, previously used with human cd T-cells by Kabelitz and colleagues [24] , and added bioluminescent analysis of tumor development, which allows early detection of tumors and temporal evaluation throughout the course of treatment, in live animals and in real-time [25] . Four weeks after tumor injection, mice that had received HMB-PP plus IL-2-treated (activated and expanded over 12 days) cd PBL showed significantly reduced tumor load (derived from Molt-4 leukemia cells) compared to control mice that did not receive cd Figures 6C-E) . Furthermore, while most control had to be sacrificed at week 4 due to excessive body weight loss, cd-treated animals resisted wasting for longer, up to week 6 (Figures 6C-D and data not shown). These results attest the capacity of HMB-PPexpanded and activated cd T-cells to induce anti-tumor responses in vivo, and support the application of this phosphoantigen in conjugation with low amounts of IL-2 in clinical cancer settings.
T-cells (

Discussion
The stimulatory effect prenyl pyrophosphates have on Vc9Vd2 T-cells has been well documented and seems to require TCR expression, as indicated by antibody blocking and gene transfer experiments [26, 27] . However, some of these experiments have been difficult to reproduce, and all attempts at showing cognate interactions between Vc9Vd2 TCRs and phosphoantigens in acellular systems (including surface plasmon resonance and X-ray crystallography of isolated complexes) have failed [15] , probably due to the requirement of an unknown phosphoantigen-presenting molecule [12] . This has raised some skepticism on phosphoantigens as TCRcd agonists, also stemming from the lack of precedent for such type of compounds interacting with any other variable region molecule, including all other cd TCRs in humans or mice. However, recent data have highlighted particular properties of HMB-PP within the large family of phophoantigens. Namely, HMB-PP induces the formation of high-density Vc9Vd2 TCR nanoclusters on the membrane of human cd T-cells [16] , and is bound on the surface of human APC by a tetramer reagent for the Vc9Vd2 TCR of rhesus macaques [17] . Following from these results on the extracellular dynamics of HMB-PP, our study aimed at clarifying the intracellular mechanisms of cd T-cell activation mediated by HMB-PP. Our results show that very low amounts of HMB-PP are able to mimic the major effects of saturating ligation of the TCRcd/CD3 complex, including the very rapid activation of MEK/Erk and PI-3K/Akt pathways to set up a transcriptional program, further enhanced by IL-2 signaling, that upregulates crucial target genes such as IFNc or TNFa and endows cells with potent anti-tumor capacity. Interestingly, HMB-PP can produce all these intracellular events without down-modulating surface TCR levels, and this may be advantageous for sustaining the cells' activation status upon re-stimulation, as suggested by our cytokine secretion data. The crucial effect of HMB-PP on Vc9Vd2 T-cells may thus be the formation of high-density surface TCR nanoclusters [16] that may serve as platforms for intracellular signaling.
Our kinetic data on signal transduction further suggest that the interaction between HMB-PP and the Vc9Vd2 TCR is much more direct/stable than those of previously studied phosphoantigens, since downstream Erk phosphorylation, for example, peaks simultaneously for HMB-PP and OKT3 treatments, in stark contrast with the delays of 115 min and 60 min, also relative to OKT3, observed respectively for the ''pioneer'' (naturallyoccurring) IPP [13] and the more recent (synthetic) BrH-PP [12] , currently in clinical trials as ''Phosphostim''. Of note, the concentration of HMB-PP we used was 50,000-fold and 3,000-fold lower than those used for IPP and BrH-PP, respectively. These data reveal a thus far unique capacity of HMB-PP to trigger very rapid TCR-associated signaling, compatible with direct binding to the Vc9Vd2 TCR, which remains to be formally shown and may require the assistance of an antigen-presenting molecule yet to identify [12, 17] . This notwithstanding, we show for the first time, using a chemical inhibition strategy, that the major cellular effects of HMB-PP -cd T cell activation, proliferation, Th1 cytokine secretion and anti-tumor cytotoxicity -are strictly dependent on Erk-and Akt-mediated signal transduction. HMB-PP stimulation therefore recruits the same signal transduction machinery employed by the cd TCR, and is capable of doing so at minimal concentrations and within a strikingly short temporal scale that distinguish it from less potent phosphoantigens, whose stimulating effects on cd T-cells most probably derive from their structural similarities with HMB-PP [3] . The use of a microbial compound for the activation of human anti-tumor lymphocytes fits the overall strategy of providing immune adjuvants (like viral nucleic acids for CD8 + T-cells) for cancer therapy. Compared to other T-cell agonists, HMB-PP offers the advantage of specifically activating a T-cell population with overt effector function, devoid of known immune suppressive (''regulatory'') subsets. Moreover, Vc9Vd2 T-cells are broadly reactive to tumors, potentially allowing them to be used to treat a variety of cancers.
The data presented in this report provide a framework for designing novel immunotherapy protocols using cd T-cells, and encourage the use of HMB-PP in clinical settings. cd T-cellmediated tumor surveillance should evidently be seen as complementary to the adaptive component provided by MHCrestricted ab T-cells upon priming by dendritic cells. Importantly, Vc9Vd2 T-cells can also induce monocyte and DC maturation [28, 29, 30] , on one hand; and even act as CD80/86-expressing antigen-presenting cells that prime ab T-cells, on the other [31] . Furthermore, cd T-cells are prototypic representatives of unconventional lymphocytes with innate anti-tumor capacity, alike NK and NKT-cells, all of which recognize tumors independently of classical MHC presentation [2] . We believe the success of cancer immunotherapy will critically depend on the integration of conventional and unconventional lymphocyte responses [32] to tackle the multiple immune evasion strategies developed by tumors.
Materials and Methods
Ethics statement
All experiments involving animals (rodents) were performed in compliance with the relevant laws and institutional guidelines and have been approved by the Instituto de Medicina Molecular animal ethics committee.
In vitro cultures of human peripheral blood lymphocytes
Peripheral blood was collected from anonymous healthy volunteers, diluted 1:1 (v/v) with PBS(16) (Invitrogen Gibco) and centrifuged in LSM Lymphocyte Separation Medium (MP Biomedicals) in a volume ratio of 3:4 (3 parts of LSM for 4 of diluted blood) for 15 minutes at 1500 rpm and 25uC. The interfase containing PBMC was collected, washed in PBS (16) and cultured at 1610 6 cells/mL at 37uC, 5% CO2 in roundbottom 96 well plates with RPMI 1640 with 2 mM L-Glutamine (Invitrogen Gibco) supplemented with 10% foetal bovine serum (Invitrogen Gibco), 1 mM Sodium Pyruvate (Invitrogen Gibco), 50 mg/mL of penicillin/streptomycin (Invitrogen Gibco), in the presence or absence of 100 U/mL of rhIL-2 (Roche Applied Science), 1-10 nM of HMB-PP (4-hydroxy-3-methyl-but-2-enyl pyrophosphate) (a kind gift from H. Jomaa and M. Eberl), and 1-10 ug/ml of soluble anti-CD3 antibody (eBioscience, clone OKT3).
For TCR blockade, freshly-isolated PBMC were CFSE-labeled and then incubated for 6 days with anti-TcRVc9 (Beckman Coulter, clone IMMU360) diluted 1:20 in complete medium supplemented with 1 nM HMB-PP.
For the phophoimmunoblotting experiments, MACS-isolated cd T cells were expanded with 100 U/mL rhIL-2 for 15 days.
To study the effects of chemical inhibitors of signal transduction, the MEK inhibitor UO126 and the PI-3K inhibitor LY294002 (both from Calbiochem) were added at 10 mM for a 2-hour incubation period, and then transferred to fresh medium (without inhibitors). 
Magnetic cell sorting and flow cytometry analysis
Protein isolation and phosphoimmunoblotting
Cells were incubated at 37uC with pre-warmed PBS alone or with HMB-PP (1 nM) or OKT3 (1 mg/mL). Reactions were stopped by placing samples on ice and adding ice-cold PBS. Cell lysates were prepared and equal amounts of protein were analyzed by 10% SDS-PAGE electrophoresis, transferred onto nitrocellulose membranes, and immunoblotted with the following mAbs or antisera: Actin, phospho-Erk (Y204) (Santa Cruz Biotechnology), ZAP-70 and phospho-STAT5A/B (Y694/Y699) (Upstate Biotechnology), phospho-Akt (S473), phospho-GSK-3b (S9), phospho-JNK/SAPK (Y183/185), phospho-p38 MAPK (Y180/182) (Cell Signalling Technology), and phospho-LCK (Y505) (Transduction Laboratories). Immunodetection was performed with horseradish peroxidase-conjugated secondary antibody and developed by chemiluminescence as described [33] . Whenever necessary membranes were striped using 15 mM TRIS pH 6.8 plus 2% SDS and b-Mercaptoethanol (100 mM) for 40 minutes at 57uC.
RNA isolation and Affymetrix GeneChip analysis
RNA labeling, hybridization to the Affymetrix GeneChip Human Genome U133 plus 2.0 Arrays and scanning was performed by the Affymetrix Core Facility, Instituto Gulbenkian de Ciencia, Portugal as described below.
Total RNA was extracted using the RNeasy Mini Kit according to manufacture's protocol (Qiagen, Hilden, Germany). Concentration and purity was determined by spectrophotometry and integrity was confirmed using an Agilent 2100 Bioanalyzer with a RNA 6000 Nano Assay (Agilent Technologies, Palo Alto, CA). RNA was processed for use on Affymetrix (Santa Clara, CA, USA) GeneChip Human Genome U133 Plus 2.0 Arrays, according to the manufacturer's One-Cycle Target Labeling Assay. Arrays were scanned on an Affymetrix GeneChip scanner 3000 7G.
All the microarray data analysis was done using R and several packages available from CRAN (R Development Core Team, 2008) and Bioconductor. The raw data (CEL files) was normalized and summarized with the Robust MultiArray Average method from the affy package.
The differentially expressed genes were selected using linear models and empirical Bayes methods as implemented in limma package, verifying the p-values corresponding to moderated Fstatistics, and selecting as differentially expressed genes those that had adjusted p-values lower than 0.005.
Real-time quantitative PCR
Total RNA was reverse-transcribed into cDNA using random hexamers and Superscript II first strand synthesis reagents (Invitrogen). qPCR was performed on ABI Prism 7700 Sequence Detection System using SYBR Green detection system (both from PE Applied Biosystems). Primers were designed using Primer3 v.0.4.0 online program (http://primer3.sourceforge.net). Primer sequences are available upon request. For each transcript, quantification was done using the calibration curve method. b2-microglobulin was used as the internal control for normalization. All samples were run in triplicate and repeated three times. Analysis of the qPCR results was performed using the ABI SDS v1.1 sequence analysis software (Applied Biosystems).
Tumor cell cultures and in vitro killing assays
All tumor cell lines were cultured in complete 10% RPMI 1640 (as above), maintained at 1610 5 up to 2610 6 cells/mL by dilution and splitting 1:3 every 3-4 days.
For cytotoxicity assays, magnetically purified cd PBL were preactivated for 72 hours with 1-10 mg/mL aCD3 mAb (OKT3) or 1-10 nM HMB-PP either in the absence or presence of IL-2 (100 U/mL). Tumor cell lines were stained with CellTracer Far Red DDAO-SE (1 mM) (Molecular Probes, Invitrogen) and each 3610 4 tumour cells were incubated with 3610 5 cd T-cells in RPMI devoid of activating compounds, for 3 hours at 37uC and 5% CO2 on a round-bottom 96 well plate. Cells were then stained with Annexin V-FITC and analyzed by flow cytometry.
Confocal microscopy
Cells were stained at 4uC with mouse anti-human TCR Vgamma9-PC5 (Beckman Coulter) primary antibody, and with anti-mouse Alexa Fluor 633 (Invitrogen, Molecular Probes) secondary antibody. Cells were then fixed with 4% Paraformaldeheyde for 15 minutes at 4uC. Nuclear DNA content was stained for with DAPI Fluoromount G (Southern Biotech). Immunofluorescence microscopy was performed with a LSM 510 META confocal microscope (Zeiss). Separate images were collected with a 636objective for each fluorochrome and then overlaid to obtain a multicolor image.
Bioluminescent imaging of transplanted leukemia development in SCID mice 10 7 Molt-4 T-cell leukemia cells stably expressing firefly luciferase and GFP were injected i.v. in groups of 6 NOD/SCID mice per experiment, either in isolation or together with 5610 7 cd PBL (.80% Vc9 + ), previously expanded and activated in vitro with 1 nM HMB-PP for 12 days. Treated mice received boosts of 5610 7 cd PBL i.v. on day 14 and 10,000 U IL-2 i.p. twice every week, whereas control mice received only IL-2. All mice were analyzed on a weekly basis by in vivo imaging (IVIS, Caliper Lifesciences) upon intra-peritoneal injection of luciferin. Photon signals were quantified with LivingImage software (Caliper Lifesciences). Mouse body weight was measured weekly, and animals suffering from wasting (loss of over 20% of initial body weight) were sacrificed.
Statistical analysis
Statistical significance of differences between subpopulations was assessed using Student's t-test and is indicated when significant as *, p,0.05; **, p,0.01; ***, p,0.001. 
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